MICROBA LIFE SCIENCES LIMITED ASX Announcement 13 April 2022
Microba CSO presents to US industry conference
For personal use only
Dr Luke Reid | Simon Hinsley |
Chief Executive Officer | Investor / Media Relations |
E:Luke.Reid@microba.com | E:simon@nwrcommunications.com.au |
T: +61 401 809 653 | |
About Microba Life Sciences Limited |
Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") is pleased to announce Chief Scientific Officer A/Professor Lutz Krause will present to microbiome research and development professionals at the 7th Annual Translational Microbiome Conference running from 13 - 14 April in Washington, DC. The virtual presentation will be delivered on Day One at 4.30PM 13 April (US EDT) / 6:30AM 14 April (AUS EST).
A copy of the presentation is attached to this announcement.
This announcement has been authorised for release by the Chairman and Chief Executive Officer.
For further information, please contact:
Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.
For more information visit:www.microba.com
Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.
Microba Life Sciences Ltd ABN 82 617 096 652
Level 10, 324 Queen Street, Brisbane QLD 4000 Australia
T: 1300 974 621 E:investor@microba.com W:microba.com
Empowering translational research outcomes with precision microbiome analysis & AI
Translational Microbiome Conference
A/Professor Lutz Krause
Chief Scientific Officer, Microba Life Sciences
April 2022 | Authorised for release by the CEO and Chairman
Microbiome science is changing medicine and will transform chronic disease management
Microbiome modulating primary and adjuvant therapies are currently being developed to address autoimmune, inflammatory, metabolic, mental health disorders and cancer immunotherapy
Microbiome therapy to treat chronic diseases
Microbiome biomarkers and signatures are being
developed for diagnosis, screening,
drug response assessment and health risk
monitoring.
Microbiome testing to match patients with the right treatment
Microba analyses the entire microbiome using proprietary technology.
Precise and comprehensive measurement unlocks this rich source of opportunity to improve human health.
Other TechnologyMicroba technology
71% of the human gut microbiome remains uncultured
Almeida et al (2021) Nature Biotechnology DOI:10.1038/s41587-020-0603-3
Illustrative visualisation of the gastrointestinal tract and the additional bacteria visible to Microba with its platform technology.
This graphic is for illustrative purposes only
9
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Microba Life Sciences Ltd. published this content on 13 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 April 2022 03:44:09 UTC.
